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Abstract
Background and purpose
Vocal fold leukoplakia, white plaque on the epithelium, has the potential for malignant trans-
formation regardless of dysplasia grade. It is treated with different laser types (CO2 or angio-
lytic) and various techniques (vaporization, stripping, or excision); however, only a few
studies exist regarding comparative laser surgery results. This study was conducted to
investigate clinical outcomes of CO2 versus angiolytic laser microdissection with regard to
long-term disease control and voice preservation in vocal fold leukoplakia.
Materials and methods
Seventy patients with vocal fold leukoplakia treated by CO2 or angiolytic laser (pulsed dye
laser or potassium titanyl phosphate) were identified retrospectively. Data regarding patient
characteristics, treatment details, treatment outcomes including disease control (recurrence
and progression) and the Voice Handicap Index, GRBAS scale, and acoustics were evalu-
ated. The mean follow-up duration after initial treatment was 32 ± 26 months.
Results
The study group comprised 14 patients who underwent CO2 laser microflap excision and 56
who underwent angiolytic laser stripping. Of the patients treated with CO2 laser, 11 (79%)
had no recurrence and three (21%) showed recurrent leukoplakia, of which one patient (7%)
showed histologic grade progression. Of patients who underwent angiolytic laser stripping,
12 had disease recurrence (21%), among whom three (5%) showed disease progression.
Laser surgery type, disease extent, and histologic grade showed no significant differences
in recurrence or progression rates. The postoperative Voice Handicap Index significantly
improved (P = .03) and the G score significantly decreased (P < .001) in the angiolytic laser
treatment group. In contrast, the Voice Handicap Index increased postoperatively in the
CO2 laser group (P = .046).
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Conclusions
The long-term recurrence or progression rates were not significantly different between
angiolytic and CO2 laser treatment. The angiolytic laser stripping group showed better voice
preservation compared with the CO2 laser group. Angiolytic laser stripping is suggested as
an effective treatment option for vocal fold leukoplakia with comparable disease control and
better voice preservation.
Introduction
Vocal fold leukoplakia is clinical terminology indicating whitish plaques on the surfaces of the
vocal folds. Vocal fold leukoplakia encompasses a variety of pathologic changes such as
(hyper)keratosis, dysplasia, carcinoma in situ (CIS), and cancer. Keratosis is an abnormal
pathologic change resulting from the production of keratin on the vocal fold epithelium. Dys-
plasia refers to abnormal keratinization on the epithelium of the vocal folds with cellular and
architectural atypia; this is considered a premalignant lesion that may lead to CIS and invasive
squamous cell carcinoma. The grade of dysplasia is assessed as mild, moderate, or severe based
on the thickness of the epithelium with cellular and architectural atypia.
A systematic review of studies from 1960 to 2005 on 2,188 patients with laryngeal leukopla-
kia showed that approximately 50% of laryngeal leukoplakia cases were benign and 50% of
cases were premalignant or malignant lesions [1]. Overall, 8.2% underwent malignant trans-
formation and the grade of dysplasia correlated with the rate of malignant transformation:
3.8% in no dysplasia, 10.1% in mild or moderate dysplasia, and 18.1% in severe dysplasia or
CIS. A recent meta-analysis of 940 cases of laryngeal dysplasia also revealed that the overall
malignant transformation rate became higher according to increasingly severe dysplasia
grades; that of mild or moderate dysplasia was 10.6% while that of severe dysplasia or CIS was
30.4% [2]. A single-institution study at Johns Hopkins Hospital revealed that the incidence of
mild dysplasia increased and that of CIS decreased in a more recent cohort, while the rate of
progression of dysplasia to cancer was unchanged (8.8% in a previous 10-year period and 8.0%
in the most recent 10-year period) [3].
Although vocal fold leukoplakia possesses malignant potential, determining the surgical
extent remains challenging due to the high incidence of benign keratosis in vocal fold leuko-
plakia and the relatively low rate of malignant transformation of premalignant vocal fold dys-
plasia. Moreover, epithelial scarring and changes in components of the layered structures of
the vocal folds result in mucosal vibration disturbance and lead to irreversible dysphonia. Con-
sidering these clinical dilemmas, microdissection of whitish plaques on vocal folds using lasers
or cold instruments has been considered an appropriate surgical treatment for vocal fold leu-
koplakia. Recently, angiolytic lasers have been employed in vocal fold leukoplakia and the sur-
gical outcomes have shown favorable results [4–8]. However, there is little literature regarding
the efficacy of angiolytic laser treatment with regard to therapeutic outcomes, especially in
comparison with CO2 laser microflap excision, which is the most commonly used surgical tool
in the treatment of vocal fold leukoplakia.
To report our experience and outline a treatment plan for vocal fold leukoplakia, we deter-
mined the clinical efficacy of laser microdissection with CO2 versus angiolytic lasers. The pri-
mary outcome measure was long-term disease control (recurrence or progression) and the
secondary outcome measure was voice preservation after vocal fold leukoplakia treatment.
Our results will provide important clues for refining surgical techniques in the treatment of
vocal fold leukoplakia.
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Methods
The Institutional Review Board of Yonsei University approved our retrospective study and
waived the requirement for patient informed consent. Patients who were treated with lasers
for vocal fold leukoplakia between 2006 and 2016 were identified from our database and their
medical records were reviewed retrospectively. Pathologic reports on biopsies from surgical
specimens were reviewed, and patients who were finally diagnosed with a benign (keratosis
without dysplasia) or premalignant lesion with the presence of dysplasia were enrolled. Cases
of invasive squamous cell carcinoma or pathologic reports without confirmation because of
insufficient material or artifacts were excluded. We only included patients treated by laser
microdissection; cases in which the surgical extent exceeded a type II cordectomy and cases
that included combined modalities with cold instruments were excluded. Patients referred for
recurrent leukoplakia who underwent surgery previously were also excluded.
Demographic information (age, sex, and smoking history), human papillomavirus (HPV)
infection, disease extent (unilateral or bilateral), laser treatment type and settings, follow-up
duration, and final disease state were reviewed from medical records. Patients were grouped
into the CO2 and angiolytic laser groups. CO2 laser surgery was conducted during the earlier
period of this study; the surgical modality transitioned to angiolytic laser surgery after pulsed
dye laser (PDL) and potassium titanyl phosphate (KTP) were introduced at our institute.
We conducted laser microdissection as follows: a CO2 microflap excision was performed
under general anesthesia. The true vocal folds were exposed using a laryngoscope and a magni-
fied view of the operative field was obtained by using a surgical microscope. After evaluation
of the disease extent based on the magnified view, the leukoplakic lesion on the mucosa was
circumferentially incised around the margin of the lesion using a CO2 laser (Sharplan 1041,
GA, USA) in 4-W super-pulse mode. A microflap was made along the subepithelial plane such
as in a type I cordectomy and the entire lesion was removed using microsurgical instruments
(Fig 1A).
Angiolytic irradiation and stripping were performed as described previously [6]. In brief,
after evaluation of the magnified vocal fold leukoplakia lesions under general anesthesia, a flex-
ible laser fiber was inserted for transmission of the angiolytic laser. The tip of the fiber was
grasped using alligator forceps and moved to its target within 3–5 mm of the lesion. An angio-
lytic laser (PDL or KTP) was used to deliver 50–70 pulses with a mean output of 600 (range,
100–700) mJ per pulse. After irradiating the entire lesion, a cleavage plane was created between
the basement membrane and leukoplakic epithelium, which was separated from the underly-
ing superficial lamina propria by denaturing the basement membrane zone linking proteins.
Then, the leukoplakic lesion can be readily elevated and stripped from the vocal folds using a
small cotton ball and grasping forceps (Fig 1B). Additional biopsies were performed at the
margins using micro scissors and the specimens were sent to the department of pathology for
histopathologic evaluation and HPV DNA testing.
Cases were divided by disease extent into the unilateral and bilateral leukoplakia groups.
Pathologic grades were rated as no dysplasia, mild/moderate dysplasia, or severe dysplasia/
CIS. The disease control rate was evaluated according to correlations with the treatment
modality (CO2 laser versus angiolytic laser), disease extent (unilateral versus bilateral), and his-
tologic grade (no dysplasia vs. dysplasia or mild/moderate vs. severe/CIS). During follow-up,
patients with disease disappearance or regression were defined as responders and those with
recurrence or with persistent or progressing lesions were defined as non-responders. Non-
responders with progression of pathologic grades were treated with serial laser surgeries with
or without radiotherapy.
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Voice assessments were conducted before and 3 months after treatment; they included
auditory-perceptual evaluation, psychometric assessment, and acoustic analysis. For percep-
tual judgment, participants were asked to read a standard Korean passage called “autumn”
aloud, which is approximately 2 minutes in length. The auditory-perceptual evaluation was
conducted on the recorded samples using the Computerized Speech Lab (Model 4150B; Kay-
PENTAX, NJ, USA) and GRBAS (grade, roughness, breathiness, asthenia, and strain) scale in
a blinded manner by two certified speech-language pathologists who determined a score in
consensus from 0 to 3 points (0, normal; 1, mild; 2, moderate; 3, severe). The Korean–Voice
Handicap Index (K–VHI) was also administered to evaluate self-perceived vocal complaints
from 0 to 4; higher scores indicate greater vocal handicaps. Acoustic analysis measurement
was performed using the Multi-dimensional Voice Program (Model 5105, KayPENTAX). As
acoustic parameters, the jitter percentage, shimmer percentage, and noise-to-harmonic ratio
(NHR) were measured from a 4-second stable portion of /a/ vowel phonation samples.
The Mann–Whitney U test was used to compare continuous variables between the CO2
laser microflap and angiolytic stripping groups. Pearson’s chi-squared test or Fisher’s exact
test was used to compare categorical variables. The Wilcoxon signed-rank test was used when
comparing two matched samples in a single patient to assess whether the mean population
ranks differed. The recurrence or progression-free rate was calculated by the Kaplan-Meier
Fig 1. The surgical processes of (A) CO2 microflap excision and (B) angiolytic stripping for vocal fold leukoplakia.
https://doi.org/10.1371/journal.pone.0209691.g001
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method. P< .05 was considered statistically significant. Statistical analyses were performed
using the Statistical Package for the Social Sciences (SPSS) version 18.0 (SPSS, Inc., Chicago,
IL, USA).
Results
The mean age of all patients was 56.87 years; 68 patients were male and two patients were
female. An angiolytic laser was used for stripping leukoplakia lesions in 56 patients and a CO2
laser microflap procedure was used in 14 patients. There were no statistically significant differ-
ences in age, sex, smoking history, HPV status, or pathologic findings between the CO2 laser
microflap and angiolytic laser stripping groups (Table 1).
Patients were divided into two groups (responders vs. non-responders) according to disease
control (Table 2). During the study period, 55 patients responded to the treatment in which
the lesion disappeared or regressed during follow-up and 15 patients had recurrent, persistent,
or progressive disease after the operation. Of the 14 patients treated using a CO2 laser, 11
patients (79%) had no recurrence and three patients (21%) showed recurrent leukoplakia. Of
the 56 patients who underwent angiolytic laser stripping, 12 patients (21%) had disease recur-
rence. There was no significant difference in the ratio of responders to non-responders accord-
ing to sex, smoking history, HPV infection status, treatment modality, disease extent, or
dysplasia grade (Table 2). There was no significant difference in the recurrence-free curve
between the angiolytic laser and the CO2 laser groups, with 40.99%, and 60.28% recurrence-
free rate at 5 years in the angiolytic laser and CO2 laser group, respectively (Fig 2A).
The overall disease progression rate of vocal fold leukoplakia was 6% in our study; however,
no lesion showed malignant transformation. Four of 15 patients with recurrence showed dis-
ease progression during the study period. Among the three patients with recurrence in the
CO2 laser microflap group, one patient (33%) showed histologic grade progression. Among 12
patients with recurrence in the angiolytic laser group, three patients (25%) showed disease pro-
gression. There was no significant relationship between disease progression and any clinico-
pathologic factor such as sex, smoking history, HPV infection status, treatment modality,
Table 1. Clinical information and treatment outcomes of all patients.
Angiolytic laser (n = 56) CO2 laser (n = 14) Total a P-value
Age (years) 56.05 ± 12.13 60.14 ± 12.94 56.87 ± 12.31 .26
Sex .28
Male 55 13 68
Female 1 1 2
Smoking (pack-years) 19.77 ± 21.27 12.86 ± 18.68 18.39 ± 20.84 .27
HPV status
Positive 2 0 2 .54
Negative 16 3 19
Not performed 38 11 49
Pathology .13
No dysplasia 36 5 41
Mild dysplasia 15 4 19
Moderate dysplasia 2 2 4
Severe dysplasia/CIS 3 3 6
a Includes 70 patients who underwent 56 anigiolytic laser stripping and 14 CO2 microflap excision.
https://doi.org/10.1371/journal.pone.0209691.t001
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disease extent, or dysplasia grade (Table 3) The progression rate per year was not significantly
different between the angiolytic laser and the CO2 laser groups (Fig 2B).
Changes in the VHI before and after treatment were analyzed. In the angiolytic laser strip-
ping group, there was a significant decrease in the VHI after treatment compared to the preop-
erative VHI value. However, in the CO2 laser microflap group, a significant increase in the
Table 2. Clinicopathologic factors related to treatment responsea.
Responders
(n = 55)
Non-responders
(n = 15)
P-value
Sex Male: 53
Female: 2
Male: 15
Female: 0
.45
Smoking
(pack-years)
17.77 ± 20.35 20.67 ± 23.13 .60
HPV statusb Positive : 2
Negative : 13
Not performed : 40
Positive : 0
Negative : 6
Not performed : 9
-
Treatment modality Angiolytic: 44
CO2: 11
Angiolytic: 12
CO2: 3
>.99
Disease extent Unilateral: 30
Bilateral: 25
Unilateral: 10
Bilateral: 5
.40
Dysplasia grade No dysplasia: 34
Mild/moderate: 15
Severe/CIS: 6
No dysplasia: 8
Mild/moderate: 6
Severe/CIS: 1
.61
a Includes 70 patients who underwent 56 angiolytic laser stripping surgeries and 14 CO2 microflap excision surgeries.
b Statistical analysis was not performed because of insufficient data. HPV: Human papillomavirus.
https://doi.org/10.1371/journal.pone.0209691.t002
Fig 2. Kaplan-Meier Curve of (A) recurrence-free and (B) progression-free rate.
https://doi.org/10.1371/journal.pone.0209691.g002
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VHI was observed after treatment compared with preoperative values (Fig 3). Changes in the
GRBAS score between before and after treatment were also compared and analyzed. In the
angiolytic laser group, the G, R, B, and S scores were decreased after treatment compared to
before treatment, but no significant difference was observed in the CO2 laser group between
before and after the operation (Fig 4). In the analysis of acoustic parameters measured using
the Multidimensional Voice Program, no significant differences were found between the
angiolytic laser group and the CO2 laser group (Table 4).
Discussion
Laryngeal dysplasia may progress to malignancy, although a relatively small proportion of dys-
plasia cases are eventually judged as premalignant lesions. Thus, management of vocal fold
Table 3. Analysis of clinicopathologic findings related to malignant transformationa.
No progression
(n = 66)
Disease progression
(n = 4)
P-value
Sex Male: 64
Female: 2
Male: 4
Female: 0
.72
Smoking
(pack-years)
15.00 ± 20.85 36.25 ± 24.62 .12
HPV statusb Positive : 2
Negative : 18
Not performed : 46
Positive : 0
Negative : 1
Not performed : 3
-
Treatment modality Angiolytic: 53
CO2: 13
Angiolytic: 3
CO2: 1
.79
Disease extent Unilateral: 37
Bilateral: 29
Unilateral: 3
Bilateral: 1
.46
Dysplasia grade No dysplasia: 40
Mild/moderate: 19
Severe/CIS: 7
No dysplasia: 2
Mild/moderate: 2
Severe/CIS: 0
.59
a Includes 70 patients who underwent 56 angiolytic laser stripping and 14 CO2 microflap excision.
b Statistical analysis was not performed due to insufficient data.
https://doi.org/10.1371/journal.pone.0209691.t003
Fig 3. Voice Handicap Index scores before and after the operation.
https://doi.org/10.1371/journal.pone.0209691.g003
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leukoplakia should encompass removal of whitish plaques from the vocal fold epithelium and
biopsy once infectious causes such as fungal laryngitis are ruled out. Surgical modalities
include ablation, stripping, and excision according to the extent of the surgical specimen
removal. A CO2 or angiolytic laser can be applied to these various surgical techniques for the
treatment of vocal fold leukoplakia. However, there is no consensus on the management of
vocal fold leukoplakia because of the clinical dilemma of balancing oncologic safety with voice
preservation after treatment. Furthermore, although there may be a temporal trend toward the
emergence of microflap excision and/or photoangiolysis, the choice of surgical option depends
on the surgeon’s preference and experience as well as the equipment and instruments available
at the hospital [3].
Along with recent advances in laser surgeries, photoangiolytic surgeries using a PDL or
KTP laser have been applied to various vocal fold lesions. These lasers can be used for ablation
of the intra- and sublesional microcirculation without excision [5, 8]. Angiolytic lasers feature
selective photothermolysis of aberrant and/or abundant microvasculature without altering the
layered structure because the wavelengths of 585 nm and 532 nm used in PDL and KTP lasers,
respectively, are near the absorption peak of hemoglobulin [5, 7]. We recently introduced a
stripping technique for vocal fold leukoplakia using a PDL angiolytic laser [6]. We first irradi-
ate the leukoplakic lesion for selective coagulation of the subepithelial microvasculature as well
as separation of the epithelium from the underlying superficial lamina propria by denaturing
the basement membrane zone linking proteins. Then, we elevate and strip the whitish plaque
off using cotton balls and grasping forceps. In contrast, a CO2 laser vaporizes the water in tis-
sues, thus enabling the cutting and excision of lesions. Traditionally, a CO2 laser has been used
for cordectomy in early glottic cancer. Although it may induce more thermal damage to the
normal tissue of the vocal fold lesions relative to angiolytic lasers, a previous study reported
Fig 4. Preoperative and postoperative GRBAS (grade, roughness, breathiness, asthenia, and strain) scores.
https://doi.org/10.1371/journal.pone.0209691.g004
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that it allows subepithelial microflap dissection such as in a type I cordectomy with a favorable
vocal outcome [9].
In this study, we investigated the efficacy of laser microdissection (CO2 microflap excision
vs. PDL or KTP angiolytic stripping) with regard to disease recurrence and progression. Our
results showed that the laser treatment modality did not affect disease recurrence rates; 12 of
56 patients (21%) in the angiolytic group and three of 14 patients (21%) in the CO2 laser group
had disease recurrence. The disease progression rate in the angiolytic laser stripping group
(three of 56 patients, 5%) was comparable to that in the CO2 laser microflap group (one of 14
patients, 7%). These favorable results suggest that angiolytic laser stripping was an effective
and safe treatment for vocal fold leukoplakia. In a retrospective study of 63 patients undergo-
ing submucosal resection using cold microlaryngeal instruments or CO2 lasers, Lee et al. dem-
onstrated that the degree of dysplasia and the extent of the lesion were factors predictive of
recurrence [10]. A recent meta-analysis indicated that treatment modality did not show a sig-
nificant effect on malignant transformation, but the risk of malignant transformation was
higher with increasingly severe dysplasia grades; the mean time to transformation was 5.8
years [2]. On the contrary, no predictive factor related to disease severity affected disease
recurrence or progression in this study. Further investigation is still required to interpret these
results because this study was performed retrospectively with a small number of patients.
In the subjective voice evaluation, the angiolytic laser stripping group showed a significant
improvement in subjective voice status compared with that in the CO2 laser microflap group.
Moreover, CO2 laser surgeries showed worse voice outcomes according to the VHI and per-
ceptual grade. A significant improvement in pitch perturbation quotient among acoustic
parameters was recently described after KTP laser therapy for laryngeal dysplasia [7]. How-
ever, in the present study, acoustic values (jitter, shimmer, and NHR) did not differ signifi-
cantly between the two treatment modalities, although antiolytic laser did not significantly
impair acoustic parameters. Given that thermal damage to the normal tissues of the vocal folds
is inevitable when using the CO2 laser microflap technique, voice quality can become more
deteriorated postoperatively after CO2 laser microflap surgery than after angiolytic laser strip-
ping surgery. However, additional investigation is required to verify the potential photother-
mal injury by angiolytic laser to delicate extravascular vocal fold tissues, according to the
power setting of laser energy delivered and exposure time.
Angiolytic laser surgeries have been conducted for the treatment of various vocal fold
lesions such as hemorrhagic polyps, nodules or cysts, and scars or sulcus [11–13]. Further-
more, office-based surgeries under local anesthesia have been advocated for the treatment of
laryngeal dysplasia or papilloma [5, 14–17]. Office-based laser irradiation under local anesthe-
sia may be less efficacious as a definitive treatment modality than that under general anesthesia
because of difficulty in positioning the laser fibers and quantifying the energy as well as the
inability to obtain biopsy samples for histologic analysis. Nevertheless, an office-based setting
Table 4. Acoustic parameters measured by Multi-dimensional Voice Program before and after the operation.
Preoperative Postoperative Mean of the differences P-value
Noise-to-harmonic ratio Angiolytic 0.167 0.181 -0.014 .82
CO2 0.175 0.174 -0.001
Jitter (%) Angiolytic 2.54 2.36 0.18 .067
CO2 2.09 3.69 -1.60
Shimmer (%) Angiolytic 5.47 5.46 0.01 .36
CO2 5.60 7.23 -1.63
https://doi.org/10.1371/journal.pone.0209691.t004
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following initial treatment in the operating room and obtaining a biopsy specimen appears to
facilitate proper disease control with minimal morbidity [3, 8].
This study includes some limitations due to its retrospective study design as follows.
The small number of patients in CO2 laser surgery may preclude a definite conclusion
regarding factors predictive of disease recurrence and progression. Disease control was deter-
mined by subjective laryngoscopic findings of leukoplakic lesions during follow-up, although
disease persistence or progression was evaluated relative to the initial endoscopic findings and
pathologic reports. It was also difficult to conclude that angiolytic laser stripping outweigh
CO2 laser microflap surgery in regards to quantitative voice quality, possibly due to the rela-
tively small number of patients who underwent CO2 laser microflap surgery. In addition, selec-
tion bias may be present because surgeons may have chosen treatment with a CO2 laser for
relatively more extensive lesions during an earlier period when there was overlap in the use of
CO2 and angiolytic lasers. Nevertheless, this study highlights for the first time that long-term
disease control using angiolytic laser stripping for the treatment of vocal fold leukoplakia was
favorable and postoperative subjective voice outcomes were better than those in CO2 laser
microflap surgery.
In our study, the angiolytic laser group showed not only comparable results in terms of
treating vocal leukoplakia but also superior voice outcomes. In addition, there were no signifi-
cant predictive factors related to disease recurrence or progression in our study. Although fur-
ther large-scale studies are required to validate our results regarding angiolytic lasers, we
confirmed that an angiolytic laser is a valid treatment option for vocal fold leukoplakia.
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